Biovitrum AB and Wyeth have extended their ReFacto supply agreement through December 31, 2015. Biovitrum will continue to be the sole producer of drug substance for Wyeth for ReFacto, as well as Xyntha/ReFacto AF, the successor products, and will continue to receive royalties from Wyeth’s global sales. Biovitrum’s co-promotion rights in the Nordic region remain unchanged. Biovitrum’s total revenues from the ReFacto business amounted to $143 million in 2007. ReFacto, Xyntha and ...